An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial

Trial Profile

An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions; Expanded access; Registrational
  • Sponsors Bayer
  • Most Recent Events

    • 05 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Jul 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2012-002104-40).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top